JAK Inhibitors and Endothelial Cardiovascular Effects

The reference study by Zavoriti and Miossec examines an important gap in JAK inhibitor research: reducing inflammatory mediators does not necessarily mean that endothelial cells have returned to a nonthrombotic state. Using human vascular endothelial cells exposed to combined tumor necrosis factor (TNF) and interleukin-17A (IL-17A), the investigators compared tofacitinib, baricitinib, upadacitinib, peficitinib, ruxolitinib, and fedratinib across inflammatory, adhesion, coagulation, and apoptosis endpoints. The full article is available through the reference study.

Study Background and Research Question

Rheumatoid arthritis and related inflammatory diseases are associated with excess cardiovascular risk. Chronic exposure to inflammatory cytokines can alter endothelial behavior, promote leukocyte recruitment, increase tissue-factor activity, suppress natural anticoagulant mechanisms, and contribute to thrombosis. TNF and IL-17A are particularly relevant because they can act synergistically in endothelial cells, increasing IL-6 and IL-8 secretion as well as expression of vascular cell adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), and E-selectin.

The JAK-STAT signaling pathway transmits signals from several cytokines, including IL-6, IL-23, and interferon-gamma. TNF and IL-17A do not directly signal through JAK-STAT, but their inflammatory network can intersect with pathways controlled by JAK-dependent cytokines. This distinction makes the study scientifically useful: a JAK inhibitor may suppress some secondary inflammatory outputs while leaving, or even aggravating, other endothelial responses.

The central question was therefore not simply whether JAK inhibitors reduce inflammation. It was whether approved inhibitors with different kinase selectivity profiles produce similar or distinct effects on endothelial dysfunction, procoagulant changes, and apoptosis during a strong TNF plus IL-17A challenge.

Key Innovation from the Reference Study

The study’s main innovation is its multidimensional comparison of endothelial responses. Many pharmacology experiments use IL-6, IL-8, or another secreted cytokine as the principal efficacy readout. Here, cytokine release was evaluated alongside adhesion molecules, tissue factor, thrombomodulin, and Annexin V staining. This design tests whether an apparent anti-inflammatory effect translates into broader vascular protection.

The comparison also places tofacitinib in the same experimental framework as JAK1-, JAK2-, pan-JAK-, and JAK1/JAK2-directed agents. In the paper, tofacitinib is characterized as an inhibitor of JAK3, JAK1, and JAK2, whereas the broader research use of Tofacitinib citrate or CP-690550 citrate often emphasizes its strong JAK3 activity. These descriptions are not interchangeable with a claim of uniform biological selectivity in every cell type or concentration range. The endothelial results demonstrate why pharmacologic class labels should be interpreted together with assay conditions and functional readouts.

Most importantly, the work separates suppression of soluble inflammation from normalization of vascular phenotype. That distinction is directly relevant to cardiovascular safety assessment and to immune regulation research using endothelial models.

Methods and Experimental Design Insights

Human vascular endothelial cells were stimulated with TNF and IL-17A to create a high-inflammatory condition. The cells were then treated or not treated with six JAK inhibitors: tofacitinib, baricitinib, upadacitinib, peficitinib, ruxolitinib, and fedratinib. Each inhibitor was tested at 1 or 10 micromolar, as reported in the published experimental design. The use of two concentrations was particularly informative because it allowed the investigators to identify responses that were retained, lost, or reversed as exposure increased.

Secreted IL-6 and IL-8 were quantified by enzyme-linked immunosorbent assay. Quantitative reverse-transcription polymerase chain reaction was used to measure changes in genes associated with leukocyte adhesion and coagulation or fibrinolysis. These included VCAM-1, ICAM-1, E-selectin, tissue factor, and thrombomodulin. Endothelial apoptosis was assessed by Annexin V staining, providing a cell-survival endpoint in addition to molecular inflammatory measurements.

This combination of assays supports a useful workflow principle: a candidate treatment should be evaluated across at least three layers of response. First, measure soluble inflammatory mediators. Second, assess endothelial activation and adhesion markers. Third, examine procoagulant, anticoagulant, and viability outcomes. Relying on only one layer could incorrectly classify a compound as vascular protective.

Protocol Parameters

• Inflammatory challenge: Expose human vascular endothelial cells to combined TNF and IL-17A to model cytokine-driven endothelial dysfunction, following the challenge framework described in the reference paper.
• JAK inhibitor comparison: Evaluate tofacitinib, baricitinib, upadacitinib, peficitinib, ruxolitinib, and fedratinib under matched conditions rather than comparing results from separate experiments.
• Concentration range: The study used 1 and 10 micromolar inhibitor conditions. These are literature parameters for this endothelial model, not universal dosing recommendations for other cell systems.
• Inflammatory readouts: Quantify IL-6 and IL-8 in conditioned medium by ELISA to distinguish broad cytokine suppression from selective effects on individual mediators.
• Vascular phenotype: Measure VCAM-1, ICAM-1, E-selectin, tissue factor, and thrombomodulin at the gene-expression level, while interpreting transcript changes as molecular indicators rather than direct evidence of clinical thrombosis.
• Viability control: Include Annexin V staining and compatible cytotoxicity controls, particularly when higher inhibitor concentrations produce unexpectedly strong or nonmonotonic responses.

Core Findings and Why They Matter

All six JAK inhibitors reduced IL-6 release from endothelial cells stimulated with TNF plus IL-17A. This shared response confirms that JAK inhibition can attenuate an inflammatory output generated by the cytokine environment, even though TNF and IL-17A themselves do not directly use the canonical JAK-STAT pathway. However, IL-8 behaved differently: only baricitinib and fedratinib reduced IL-8 overproduction at the lower tested concentration, according to the comparative results.

The adhesion-molecule results were more complex. Fedratinib reduced VCAM-1 and E-selectin induction at both tested concentrations. Tofacitinib reduced ICAM-1 and E-selectin induction at the lower concentration. In contrast, at the higher concentration, tofacitinib, baricitinib, upadacitinib, peficitinib, and ruxolitinib enhanced TNF plus IL-17A-induced VCAM-1 and ICAM-1 expression. This concentration-dependent reversal is one of the paper’s most important observations because it cautions against interpreting greater exposure as automatically more protective.

Coagulation-related endpoints further separated the inhibitors. Peficitinib and fedratinib reduced tissue-factor up-regulation at both concentrations, while ruxolitinib did so only at the lower concentration. None of the tested compounds prevented the cytokine-induced loss of thrombomodulin, an endogenous anticoagulant molecule. Thus, inhibition of selected proinflammatory outputs did not restore the balance between procoagulant and anticoagulant endothelial programs.

Finally, peficitinib and fedratinib showed proapoptotic and cytotoxic effects in the endothelial system. This finding complicates a simple ranking based on cytokine suppression: a compound that lowers a secreted mediator but damages endothelial cells may not provide a favorable overall vascular profile. The broader implication is that endothelial inflammation, adhesion, coagulation, and survival should be treated as related but nonredundant pharmacology endpoints.

Comparison with Existing Internal Articles

The internal article Distinct Vascular Impacts of JAK Inhibitors in Endothelial Inflammation is closely aligned with the reference paper because it also emphasizes inhibitor-specific effects on cytokines, adhesion molecules, and procoagulant responses. It can serve as a focused companion when planning an endothelial inflammation panel, while the reference study remains the primary source for the comparative findings discussed here.

A second relevant resource, JAK Inhibitors and Endothelial Cardiovascular Risk, places the experimental observations in the context of cardiovascular safety interpretation. Its practical value is greatest when designing studies that distinguish cytokine reduction from vascular normalization. Neither internal article replaces clinical evidence; both are best used to organize assay selection and interpretive questions around the published endothelial results.

Limitations and Transferability

The model is an in vitro endothelial system exposed to a deliberately intense TNF plus IL-17A stimulus. It does not reproduce the full cellular, hemodynamic, metabolic, and pharmacokinetic environment of rheumatoid arthritis, myeloproliferative neoplasms, or another inflammatory disorder. In particular, the experiment does not include circulating leukocytes, platelets, liver metabolism, blood flow, or the tissue-level interactions that influence cardiovascular events.

The tested micromolar conditions also require careful interpretation. A concentration that produces a useful mechanistic contrast in cultured cells should not be treated as a clinical exposure estimate without additional pharmacokinetic and free-drug analyses. The study further evaluates acute molecular and viability responses rather than long-term endothelial remodeling or prospective cardiovascular outcomes.

Transferability is therefore strongest at the level of experimental logic: compare multiple inhibitors, use matched exposure conditions, and measure soluble inflammation together with adhesion, coagulation, and apoptosis. Transferability is weaker for ranking clinical cardiovascular risk directly. The findings support hypothesis generation and assay design, not a clinical conclusion that one inhibitor will produce a specific event profile in every patient population.

Research Support Resources

For similar immune regulation research and inflammatory disorder research workflows, researchers can use Tofacitinib citrate (CP-690550 citrate) (SKU A4135) as an experimental JAK inhibitor. The product information reports approximately 1 nM inhibitory potency against JAK3 and describes applications involving the JAK-STAT signaling pathway, lymphocyte proliferation inhibition, and modulation of Th1, Th2, Th17, and regulatory T-cell responses. These properties make it useful for controlled pathway studies, but concentrations should be selected for the specific cell type and assay rather than copied directly from the endothelial paper. For vascular experiments, pair cytokine measurements with adhesion, tissue-factor, thrombomodulin, and viability readouts so that anti-inflammatory activity is not mistaken for complete endothelial protection.